Pilotte Amy Potter
Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute , Boston, MA , USA.
Curr Med Res Opin. 2015;31(7):1363-76. doi: 10.1185/03007995.2015.1045470. Epub 2015 Jun 8.
Gastrointestinal stromal tumor (GIST), a form of soft tissue sarcoma, is often detected incidentally or at an advanced stage. The tyrosine kinase inhibitor sunitinib malate (Sutent * ) is established as second-line treatment for the management of GIST after disease progression on, or intolerance to, first-line imatinib treatment. Several published reviews give guidance on management of side effects in patients with advanced renal cell carcinoma treated with sunitinib, but fewer publications cover side-effect management in patients with GIST.
Using published articles and abstracts, prescribing information, and personal experience in managing patients with GIST at a specialized center of excellence for cancer care, I review side-effect management recommendations for patients with GIST treated with sunitinib and provide an overview of GIST.
Sunitinib has a well described side-effect profile: most side effects occurring in patients with GIST can be easily managed by standard medical intervention and/or dose modification.
Care of patients with GIST can be enhanced through communication, support, knowledge, and education, with the goal of providing effective therapy and optimal symptom control.
胃肠道间质瘤（GIST）是软组织肉瘤的一种形式，通常是偶然发现或在晚期才被检测到。酪氨酸激酶抑制剂苹果酸舒尼替尼（索坦*）被确立为一线伊马替尼治疗后疾病进展或不耐受时GIST管理的二线治疗药物。一些已发表的综述为接受舒尼替尼治疗的晚期肾细胞癌患者的副作用管理提供了指导，但涉及GIST患者副作用管理的出版物较少。
利用已发表的文章和摘要、处方信息以及在癌症护理专业卓越中心管理GIST患者的个人经验，我回顾了接受舒尼替尼治疗的GIST患者的副作用管理建议，并对GIST进行了概述。
舒尼替尼的副作用特征已得到充分描述：GIST患者出现的大多数副作用可通过标准医疗干预和/或剂量调整轻松管理。
通过沟通、支持、知识和教育可以加强对GIST患者的护理，目标是提供有效的治疗和最佳的症状控制。
